A STING-activating nanovaccine for cancer immunotherapy.

导出 OA

翻译打印收藏纠错

作者： Min,Luo ^[1] ; Hua,Wang ^[2] ; Zhaohui,Wang ^[1] ; Haocheng,Cai ^[2] ; Zhigang,Lu ^[3] ; Yang,Li ^[1] ; Mingjian,Du ^[2] ; Gang,Huang ^[1] ; Chensu,Wang ^[1] ; Xiang,Chen ^[2] ; Matthew R,Porembka ^[4] ; Jayanthi,Lea ^[5] ; Arthur E,Frankel ^[6] ; Yang-Xin,Fu ^[7] ; Zhijian J,Chen ^[2] ; Jinming,Gao ^[8]

作者单位： Department of Pharmacology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA. ^[1] Department of Molecular Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA. ^[2] Department of Developmental Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA. ^[3] Department of Surgery, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA. ^[4] Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA. ^[5] Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA. ^[6] Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA. ^[7] Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA. ^[8]